Following $30M NIH Deal, Kalypsys Continues Internal Drug Discovery Work | GenomeWeb

“We’re not a screening or tools company; we’re a drug discovery company.” Such is the adamant mantra of Kalypsys’ president and CEO John McKearn.

However, the screening technology and tools used by the San Diego-based company for its own drug discovery are apparently viewed as a valuable commodity. In June, the National Institutes of Health’s newly established Chemical Genomics Center selected Kalypsys to provide it with a suite of ultra-high throughput screening technologies in a deal that could be worth $30 million over the next four years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.